Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
Trial Details
- NCT ID
- NCT05444478
- Phase
- NA
- Sponsor
- Sun Yat-sen University
- Status
- RECRUITING
- Cancer Type
- Liver Cancer
- Interventions
- Microwave ablation
- Lenvatinib
- Locations (sample)
- Changsha, Hunan, China|28.19874,112.97087
Key Eligibility Criteria
- Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma;
- recurrent HCC without any tumor related therapy;
- Tumor number ≤3;
- Tumor size ≤5cm;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →